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Abstract Glycogen storage diseases type 1 (GSD 1) are a group
of autosomal recessive disorders characterized by impairment of
terminal steps of glycogenolysis and gluconeogenesis. Mutations
of the glucose-6-phosphatase gene are responsible for the most
frequent form of GSD 1, the subtype 1a, while mutations of the
glucose-6-phosphate transporter gene (G6PT) have recently been
shown to cause the non 1a forms of GSD, namely the 1b and 1c
subtypes. Here, we report on the analysis by single-stranded
conformation polymorphism (SSCP) and/or DNA sequencing of
the exons of the G6PT in 14 patients diagnosed either as affected
by the GSD 1b or 1c subtypes. Mutations in the G6PT gene were
found in all patients. Four of the detected mutations were novel
mutations, while the others were previously described. Our
results confirm that the GSD 1b and 1c forms are due to
mutations in the same gene, i.e. the G6PT gene. We also show
that the same kind of mutation can be associated or not with
evident clinical complications such as neutrophil impairment.
Since no correlation between the type and position of the
mutation and the severity of the disease was found, other
unknown factors may cause the expression of symptoms, such as
neutropenia, which dramatically influence the severity of the
disease.
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1. Introduction
Glycogen storage disease type 1 (GSD 1 or von Gierke
disease) includes a clinically, biochemically and genetically
heterogeneous group of autosomal recessive disorders [1].
The basic defects reside in the impairment of the terminal
steps of glycogenolysis and gluconeogenesis, at di¡erent levels.
Mutations of the glucose-6-phosphatase gene (G6Pase),
which lead to the enzyme de¢ciency, are responsible for the
most frequent form of GSD 1, the subtype 1a [1]. This gene is
not mutated in patients in which there are biochemical evi-
dences of defects in the glucose-6-phosphate transport system
[2]. GSD 1 patients diagnosed as non 1a have been subdivided
at least in 1b and 1c subtypes on the basis of clinical and
biochemical parameters [1]. The recent cloning of the cDNA
for a putative endoplasmic reticulum glucose-6-phosphate
transporter (G6PT) [3] has enabled the search for mutations
in this gene in GSD 1 non a patients [4^9]. Recent data from
others [5^9] indicate that mutations in the G6PT gene are
present in both 1b and 1c patients so far investigated.
We report on the genetic analysis of 14 additional patients
a¡ected by GSD 1 non a. Six of them were clinically and
biochemically diagnosed as 1b subtypes, ¢ve as 1c subtypes
and three simply as 1 non a forms. Mutations of the G6PT
gene were detected in all cases. Four of the mutations detected
were novel, while the others were previously described.
Although the mutations appear to be scattered throughout
the entire G6PT gene, there seems to be a proportionally
higher number of mutations in exons 3 and 8. Present and
previously reported data [5^9] strongly suggest that the G6PT
gene is involved in most, if not all, of the GSD 1 non a cases.
2. Materials and methods
2.1. Patients
DNAs from 14 non 1a GSD patients and from their parents, when
available, were collected. Two patients (no. 38 and 39) were siblings.
The Caucasian ethnic background is common for all the patients
studied. In 11 patients (no. 22, 25, 28, 32, 35, 37^41 and 49), the
diagnosis for GSD 1b or 1c was based on clinical features (hepato-
megaly, hypoglycemia and lactic acidosis) and on kinetic analysis of
G6Pase system activity in liver biopsy samples [1]. Patients 42, 43 and
44 were simply diagnosed as type 1 non a, since (in addition to the
clinical symptoms as above) no mutations were found in the glucose-
6-phosphatase enzyme gene. Neutropenia and impaired neutrophil
function were clinically evident in seven out of the 14 patients inves-
tigated.
2.2. Mutational analysis
Peripheral blood lymphocytes isolated from all the individuals were
used for extraction of genomic DNA using a standard protocol [4].
All the nine exons of the G6PT gene were ampli¢ed by the polymer-
ase chain reaction (PCR), using the intronic primers described else-
where [4] and subsequently screened by single-strand conformation
polymorphism (SSCP) analysis. PCR reactions were performed in
25 Wl containing 100 ng of genomic DNA, 1UPCR bu¡er (Perkin-
Elmer), 0.5 pmol/l of each primer, 180 WM of each dNTP and 1 U Taq
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DNA polymerase (Perkin-Elmer). The PCR conditions were 95‡C for
5 min and then 30 cycles at 95‡C for 40 s, 60‡C for 30 s and 72‡C for
30 s and the ¢nal extension was 72‡C for 4 min. The ampli¢ed sam-
ples were diluted 1:1 in formamide bu¡er (95% formamide, 10 mM
NaOH, 0.025% bromophenol blue and 0.025% xylene cyanol), dena-
tured at 95‡C for 5 min and cooled on ice. Four^8 Wl of PCR prod-
ucts was loaded on a non-denaturing polyacrylamide gel containing
6% acrylamide, prepared with a 99:1 ratio between acrylamide and
bis-acrylamide. Gels were run in a cold room for 1^4 h at 30 W. DNA
bands were visualized by silver staining. PCR products that revealed
an aberrant conformer were ¢rst re-con¢rmed by an independent PCR
and than puri¢ed using Qiagen puri¢cation columns according to the
manufacturer’s instructions and both strands were sequenced using
the Sequenase 2.0 kit (USB). In the cases in which the SSCP method
did not allow us to detect conformational variants (four mutations in
four patients), direct sequencing of all the exons was performed.
3. Results
SSCP analysis and DNA sequencing of the coding region
and exon-intron boundaries of the G6PT gene allowed us to
identify causative mutations in all of the 14 patients investi-
gated, who have been diagnosed as GSD type 1b, 1c or 1 non
a (Table 1). Collectively, 13 di¡erent mutations were detected
(Table 1) and four novel mutations were identi¢ed. A dinu-
cleotide (GG) insertion after nucleotide 514 in exon 2 was
found in both alleles of patient 22, which results in a change
in the reading frame after Gly-115 and premature termination
of translation after amino acid 128 (reading frame shift (RFS)
after Gly-115, Stop at 128). Patients 25 and 35 were found to
carry a 693^696delTGTG mutation in exon 3, inherited from
the mother in both cases, causing a change in the reading
frame after Ala-174 and termination of translation after ami-
no acid 210 (RFS after Ala-174, Stop at 210). Patient 25 was
found to carry also the missense mutation previously reported
as C251T, changing the Arg-28 to Cys [5]. This mutation of
paternal origin was detected through direct sequencing, while
no other mutation was found in patient 35 in the remaining
allele, although all the exons and exon-intron junctions were
sequenced. Patient 42 showed a G to A transition in position
1068, leading to the Arg-300-His substitution in exon 6 pre-
viously described [4]. In this patient, we detected, after direct
sequencing, another novel mutation (G580A) leading to a
Trp-137-Stop in exon 3. An additional novel point mutation
(G1268A) in exon 8 which leads to a Ala-367-Thr substitution
was found in patient 44, together with a nonsense mutation
(C911T) previously reported [5], which causes the substitution
of the codon for Gln in position 248 with a stop codon. All
the other patients carry mutations previously described. Pa-
tient 28 carried a G371A mutation (detected through direct
sequencing), which leads to a Gly-68-Arg change in exon 2 [5]
and a silent mutation in exon 9 (G1393A, codon 408) already
described [5]. No other pathogenic mutation was found in the
other allele. Patient 32 was found to be homozygous for the
frequently detected 2 bp deletion (1211^1212 CT) in exon 8
[5].
The C911T mutation was detected also in patient 37, who,
in addition, carried the 1211^1212 CT deletion. Patient 43
carried the 1211^1212 CT deletion and the T716C mutation
in exon 3, changing Cys-183 to Arg in the other allele [8].
Among the GSD 1c patients, two brothers (patients 38 and
39) were homozygous for a G228A nucleotide substitution
which causes a Gly-20-Asp substitution in exon 1 [5]. Patient
40 was found to be homozygous for a Gly-149-Glu in exon 3
(G615A) [8]. Patient 41 was found to be homozygous for a
7 bp deletion (338^344 TCGGCAG del) in exon 2, which
results in a frameshift after Gln-56 and premature termination
of translation (RFS after Gln-56, Stop at 72) [8]. Patient 49
Table 1
Mutations identi¢ed in 14 GSD 1b/1c patients
Patient Diagnosis Neutropenia Mutation E¡ect on amino acid sequence
22 1b 3 514insGG (exon 2)* RFS after Gly-115. Stop at 128
514insGG (exon 2) RFS after Gly-115. Stop at 128
25 1b + 693^696delTGTG (exon 3)* RFS after Ala-174. Stop at 210
C251T (exon 1) Arg-28-Cys
28 1b + G371A (exon 2) Gly-68-Arg
G1393A (exon 9) Silent
32 1b + 1211^1212delCT (exon 8) RFS after Ala-347. Stop at 400
1211^1212delCT (exon 8) RFS after Ala-347. Stop at 400
35 1b + 693^696delTGTG (exon 3) RFS after Ala-174. Stop at 210
37 1b + C911T (exon 4) Gln-248-Stop
1211^1212delCT (exon 8) RFS after Ala-347. Stop at 400
38 1c 3 G228A (exon 1) Gly-20-Asp
G228A (exon 1) Gly-20-Asp
39 1c 3 G228A (exon 1) Gly-20-Asp
G228A (exon 1) Gly-20-Asp
40 1c 3 G615A (exon 3) Gly-149-Glu
G615A (exon 3) Gly-149-Glu
41 1c 3 338^344delTCGGCAG (exon 2) RFS after Gln-56. Stop at 72
338^344delTCGGCAG (exon 2) RFS after Gln-56. Stop at 72
42 1 non a + G1068A (exon 6) Arg-300-His
G580A (exon 3)* Trp-137-Stop
43 1 non a + T716C (exon 3) Cys-183-Arg
1211^1212delCT (exon 8) RFS after Ala-347. Stop at 400
44 1 non a 3 C911T (exon 4) Gln-248-Stop
G1268A (exon 8)* Ala-367-Thr
49 1c 3 1211^1212delCT (exon 8) RFS after Ala-347. Stop at 400
1211^1212delCT (exon 8) RFS after Ala-347. Stop at 400
RFS, reading frame shift. The position of mutations is given according to the numbering of the previously published cDNA sequence [3]. An
asterisk (*) indicates a novel mutation.
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was found to be homozygous for the 2 bp deletion (1211^1212
CT) in exon 8.
4. Discussion
Identi¢cation of the G6PT cDNA [3] and characterization
of the structure of the gene [4^7] has allowed us to carry out
mutational analysis of the G6PT gene in 14 patients who have
been diagnosed as GSD type 1b, 1c and 1 non a (Table 1).
Present results are in agreement with other recent reports [5^
9], which indicate that this gene is the cause of the majority of,
if not all, GSD 1b and 1c. Seven patients (including two
siblings) were homozygous for the identi¢ed mutation in the
G6PT gene (Table 1). The other seven patients resulted to be
heterozygous: ¢ve of them were characterized in both the
alleles, whereas in the other two patients, SSCP analysis and
complete sequencing revealed mutations in only one allele
(Table 1, patients 28 and 35). The incompleteness in revealing
all mutations might be ascribed to mutations in the 5P and 3P
untranslated regions, since genetic heterogeneity has not been
reported to date.
Overall, nine di¡erent single nucleotide substitutions, three
deletions and one insertion account for 26 mutations found
out of 28 chromosomes: no major rearrangements were ob-
served (Table 1). We have identi¢ed four novel mutations in
the G6PT gene: a dinucleotide insertion (514insGG), a four
base deletion (693^696delTGTG), a nonsense mutation
(G580A) and a missense mutation (G1268A). Including these,
the known mutations of the G6PT rise to 37 as summarized in
Table 2.
An important observation arising from the presently avail-
able data (Table 2) is that the same mutation has been found
either in GSD 1b or GSD 1c diagnosed patients. In the
present study, the Gly-20-Asp and the Gly-149-Glu, previ-
ously described in GSD 1b patients [5,8], were respectively
found in three GSD 1c patients (siblings 38 and 39 and pa-
tient 40). Moreover, the 338^344delTCGGCAG mutation
causing a RFS after Gln-56 and the production of a truncated
protein was ¢rst described in a 1b patient [8] and in the
present work, we found it in a 1c patient (patient 41). Addi-
tional examples con¢rm that the G6PT gene is involved in one
non a subtype of GSD. The four amino acid repeat after Met-
311 and the splice site mutation between exon 8 and intron 8
(1292+3delaagt) have both been described either in 1b or 1c
patients [5]. It may be noteworthy to highlight that also the
most frequent mutation of the G6PT gene (1211^1212del CT)
Table 2
Nucleotide change Exon E¡ect on amino acid sequence Frequency % References
Missense mutations
G1184T 8 Gly-339-Cys (TR 8) 8.7 [3,5]
G228A 1 Gly-20-Asp (TR 1) 4.8 [5]
T521C 2 Trp-118-Arg (CL 1) 4.0 [6,10]
G252A 1 Arg-28-His (IL 1) 3.2 [8]
G615A 3 Gly-149-Glu (TR 3) 3.2 [8]
C251T 1 Arg-28-Cys (IL 1) 1.6 [5]
G371A 2 Gly-68-Arg (IL 1) 1.6 [5]
G431A 2 Gly-88-Asp (TR 2) 1.6 [5]
T716C 3 Cys-183-Arg (TR 4) 1.6 [8]
G1068A 6 Arg-300-His (CL 3) 1.6 [4]
A332C 2 Ser-55-Arg (IL 1) 0.8 [5]
G617A 3 Gly-150-Arg (TR 3) 0.8 [5]
G1268A 8 Ala-367-Thr (TR 9) 0.8 Novel
Nonsense mutations
C911T 4 Gln-248-Stop 4.8 [5,8]
G1348A 9 Trp-393-Stop 1.6 [8]
G1232T 8 Glu-355-Stop 0.8 [3,5]
G456A 2 Trp-96-Stop 0.8 [5]
G580A 3 Trp-137-Stop 0.8 Novel
C821T 4 Gln-218-Stop 0.8 [5]
Deletions/insertions
1211^1212delCT 8 vRF after Ala-347, Stop at 400 20.6 [4,5,8,9]
338^344delTCGGCAG 2 vRF after Gln-56, Stop at 72 3.2 [8]
350delG 2 vRF after Tyr-60, Stop at 94 1.6 [4]
514insGG 2 vRF after Gly-115, Stop at 128 1.6 Novel
629delA 3 vRF after Pro-153, Stop at 211 1.6 [5]
693^696delTGTG 3 vRF after Ala-174, Stop at 210 1.6 Novel
1094delGCTG/insTC 6 vRF after Met-308, Stop at 323 1.6 [6]
1103ins12 6 Four amino acid repeat after Met-311 1.6 [5]
1105insA 6 vRF after Thr-312, Stop at 325 1.6 [5]
1094delG 6 vRF after Met-308, Stop at 311 0.8 [4]
1205insC 8 vRF after Pro-345, Stop at 401 0.8 [5]
Splice site mutations
1292+3delaagt (TGgtaagtgttCTGgtgtt) E. 8/ I. 8 Truncated protein? 6.3 [5]
317+1 GCT (GGgtCGGtt) E. 1/I. 1 Truncated protein? 1.6 [9]
1293-2delag (cagTGCcTG) I. 8/E. 9 Truncated protein? 1.6 [5]
317+1 GCA (GGgtCGGat) E. 1/I. 1 Truncated protein? 0.8 [6]
318-2 ACC (agGGCcgGG) I. 1/E. 2 Truncated protein? 0.8 [10]
550+1 GCT (AGgtCAgtt) E. 2/I. 2) Truncated protein? 0.8 [8]
1041ins9 (agGCGGCagGCTCCATAGGCGG) I. 5/E. 6 Gly-292-Pro Leu-293-Stop 0.8 [5]
CL, cytosolic loop; IL, intraluminal loop and TR, transmembrane region according to the model proposed by Pan et al. [11].
FEBS 22688 30-9-99
L. Galli et al./FEBS Letters 459 (1999) 255^258 257
has already been described either in GSD 1b or 1c patients
[4,5,8,9]. In the present set of patients, the 1211^1212del CT
was found in four patients: in the homozygous state in pa-
tients 32 and 49 (1b and 1c, respectively) and in the hetero-
zygous state in patients 37 and 43 (1b and non 1a, respec-
tively). It can be concluded, therefore, that not only the same
gene is involved in both GSD 1b and 1c subtypes, but that no
speci¢c mutation is associated to each of the two subtypes.
Interestingly, the same mutation in the G6PT gene is not
necessarily associated with the appearance of a clinically evi-
dent neutrophil impairment. Patient 32 was diagnosed as
GSD 1b patient, su¡ers from neutrophil dysfunction and
has the same kind of mutation in the homozygous state
(1211^1212delCT), characterizing patient 49, who was diag-
nosed as GSD 1c and does not show symptoms of neutrophil
impairment. In addition, a previously reported GSD 1 non a
patient a¡ected by severe neutropenia was found to be homo-
zygous for Gly-149-Glu mutation [8], whilst patient 40, who is
also homozygous for Gly-149-Glu mutation, has no evident
neutrophil dysfunction. These observations indicate that neu-
trophil impairment, which often has been assumed to be a
distinctive feature of GSD 1b, cannot be considered so any-
more.
Although the mutations appear to be scattered throughout
the entire G6PT gene, there seems to be a proportionally
higher number of mutations in exons 3 and 8. According to
the model proposed by Pan [11] for the transmembrane top-
ology of G6PT, we conclude that the mutations we detected
are equally distributed in the transmembrane region, in the
luminal side and in the cytoplasmic side. This is also true if we
take into consideration all the known mutations of the G6PT
gene. All the known missense mutations causing amino acid
substitutions in the transmembrane region of the protein are
responsible for the conversion of a hydrophobic amino acid to
a hydrophilic amino acid, Gly-339-Cys. This can possibly
cause an abnormal folding of the transporter in the ER mem-
brane and, consequently, a functional anomaly. On the other
hand, nonsense mutations and insertion/deletion mutations
cause the synthesis of a truncated protein missing the two
lysines at the carboxy-terminus necessary as a retention signal
in the ER membrane [3] and therefore do not allow for glu-
cose-6-phosphate transport. Overall, what is clear from our
data and results coming from other labs [4,10] is that there is
no correlation between the type and position of the genetic
damage and the severity of the disease. For example, patient
41 has a possibly non-functional transporter protein because
of an early truncation, but the clinical pro¢le is quite good as
in patients 38 and 39 who have an amino acid substitution
instead of a truncated protein so that the transporter, though
mutated, can still be inserted in the ER membrane. In addi-
tion to this, it should be considered that the same kind of
mutation could be associated or not with clinical complica-
tions such as neutrophil impairment. We have already men-
tioned the 1211^1212delCT mutation that has been described
either in patients with neutrophil de¢ciency or in patients not
showing this type of alteration. Therefore, on the basis of the
data actually available, it should be concluded that there must
be other factors, unknown yet, in£uencing the appearance of
symptoms such as neutropenia, dramatically in£uencing the
clinical severity of the disease.
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